MAP3K14 and prostate carcinoma: BIRC3 is associated with chemotherapy resistance in Ewing sarcoma, rhabdomyosarcoma [64] and prostatic cancer [65] and suppresses TNFalpha mediated cell death by preventing formation of TNF Receptor 1. It regulates pro-survival NFKB-signalling by promoting degradation of MAP3K14 [66].